Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma
https://sci-hub.tw/10.1200/JCO.19.03327
- out of 35 patients with nonenhancing glioma, objective response rate was 2.9% with one partial response
- of these same patients, 30/35 (85.7%) had stabilization of their disease.
- for these same 35 patients, median progression-free survival was 13.6 months.
- the drug was well-tolerated with no dose-limiting toxicities reported.
As seen here, many of the patients with non-enhancing glioma have had disease stabilization for three years or more. Not bad for a drug that is so well tolerated and with no dose-limited toxicities.
No comments:
Post a Comment